0GQU.L
ACTIVE BIOTECH AB ACTIVE BIOTEC
£0.04
+6.60%
2026-02-20
About ACTIVE BIOTECH AB ACTIVE BIOTEC
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Key Fundamentals
EPS (TTM)
£-0.25
ROE
-84.5%
Profit Margin
0.0%
Debt/Equity
3.12
Price/Book
3.29
Beta
1.33
Market Cap
£8.2M
Recent Breakout Signals
No recent breakout signals detected for 0GQU.L.
Recent Price Range (60 Days)
60D High
£0.04
60D Low
£0.04
Avg Volume
30.8M
Latest Close
£0.04
Get breakout alerts for 0GQU.L
Sign up for Breakout Scanner to receive daily notifications when 0GQU.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ACTIVE BIOTECH AB ACTIVE BIOTEC (0GQU.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0GQU.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.